Covid-19
Germany approves clinical trial of coronavirus immunity vaccines
Germany has approved clinical trials of multiple vaccines developed by German biotech company, BioNTech, for treatment of coronavirus. Scientists were said to be monitoring the effectiveness of the vaccines in generating immunity against coronavirus. The clinical trial will be starting with 200 participants of 18 to 55 years age bracket.
Statistics from Johns Hopkins University shows that coronavirus has killed over 177,000 people and infected 2.5 million across the world. This was identified to have given impetus to the race to develop vaccines that can contain the spread of coronavirus and the associated deaths across the world.
About 86 teams were identified to be engaged on research and study for coronavirus vaccines across the world.
-
Featured6 days agoInside INEC’s race to prepare for Nigeria’s 2027 elections
-
Latest1 week agoGlobal excitement builds as Healing Streams Live Services returns October 23
-
Featured6 days ago2027: APC unveils nationwide campaign timetable, Tinubu to rally in 12 states
-
Business1 week agoPresident Tinubu and the Low Transport Fares Fiasco
-
Business3 days agoNaira faces exchange rate gap as Dollar hits N1,380 on parallel market
-
Business6 days agoCourt dismisses ₦170m Trade Fair contract claim, says Zenith Bank was not a party
-
Latest6 days agoBreaking: NNPCL raises petrol price to ₦1,405 per litre amid discount controversy
-
Business1 week agoRite Foods targets beverage market growth with LIDA Malt